Encompass Health (NYSE:EHC) Announces Earnings Results, Beats Expectations By $0.19 EPS

Encompass Health (NYSE:EHC) released its earnings results on Wednesday. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.19, Briefing.com reports. Encompass Health had a net margin of 7.33% and a return on equity of 17.69%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the previous year, the firm earned $0.88 earnings per share. Encompass Health’s revenue was up 13.4% compared to the same quarter last year. Encompass Health updated its FY24 guidance to $3.86-4.11 EPS.

Encompass Health Stock Up 0.1 %

Shares of EHC stock traded up $0.06 on Thursday, hitting $82.86. The stock had a trading volume of 472,170 shares, compared to its average volume of 659,412. The firm has a market capitalization of $8.30 billion, a price-to-earnings ratio of 23.57, a P/E/G ratio of 1.53 and a beta of 0.94. The stock’s 50 day moving average is $77.89 and its 200-day moving average is $70.67. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.28 and a current ratio of 1.28. Encompass Health has a 52-week low of $57.55 and a 52-week high of $85.84.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were paid a $0.15 dividend. The ex-dividend date of this dividend was Thursday, March 28th. This represents a $0.60 annualized dividend and a dividend yield of 0.72%. Encompass Health’s dividend payout ratio (DPR) is presently 17.29%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on EHC. Truist Financial boosted their target price on shares of Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a report on Friday, February 9th. Stephens restated an “overweight” rating and issued a $85.00 target price on shares of Encompass Health in a report on Tuesday, January 16th. William Blair restated an “outperform” rating on shares of Encompass Health in a report on Wednesday, February 7th. Mizuho boosted their price objective on shares of Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Barclays boosted their price objective on shares of Encompass Health from $95.00 to $101.00 and gave the stock an “overweight” rating in a research note on Thursday, March 28th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $84.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.